J2KBIO (A420570) 주식 개요바이오 벤처기업인 제이투케이바이오(주)는 천연 소재와 미생물 발효를 통해 화장품, 기능성 식품, 생활용품의 유효 성분을 생산하는 기업입니다. 자세히 보기A420570 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적4/6재무 건전성6/6배당2/6강점가격 대비 수익 비율(11.2x)은 Biotechs 업계 평균(24.2x)보다 낮습니다.지난 1년간 수익이 39.4% 증가했습니다.위험 분석지난 5년간 매년 수익이 3% 감소했습니다.의미 있는 시가총액이 없습니다(₩45B)모든 위험 점검 보기A420570 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW486,676 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG486,676 investors already sharing narrativesYour Fair Value₩Current Price₩7.74k40.5% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-312m37b2016201920222025202620282031Revenue ₩36.8bEarnings ₩4.0bAdvancedSet Fair ValueView all narrativesJ2KBIO Co., Ltd. 경쟁사GeneBioTech LtdSymbol: KOSDAQ:A086060Market cap: ₩39.2bBIO-FD&CLtdSymbol: KOSDAQ:A251120Market cap: ₩71.9bSeoulin BioscienceLtdSymbol: KOSDAQ:A038070Market cap: ₩38.8bPanGen BiotechSymbol: KOSDAQ:A222110Market cap: ₩61.9b가격 이력 및 성과J2KBIO 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩7,740.0052주 최고가₩11,850.0052주 최저가₩6,710.00베타0.501개월 변동6.46%3개월 변동0.13%1년 변동-23.29%3년 변동n/a5년 변동n/aIPO 이후 변동-70.23%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,510, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 14% over the past year.Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 7.0% to ₩8,050. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 19%.Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,790, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past year.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year.Buy Or Sell Opportunity • Apr 09Now 20% overvaluedOver the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,510, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 14% over the past year.Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 7.0% to ₩8,050. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 19%.Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,790, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past year.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year.Buy Or Sell Opportunity • Apr 09Now 20% overvaluedOver the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Mar 05Now 22% overvaluedOver the last 90 days, the stock has fallen 7.1% to ₩7,800. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.공시 • Feb 13J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South Korea분석 기사 • Dec 17J2KBIO Co., Ltd.'s (KOSDAQ:420570) Prospects Need A Boost To Lift SharesJ2KBIO Co., Ltd.'s ( KOSDAQ:420570 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,720, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 3.8% over the past year.Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ₩143 (vs ₩45.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩143 (up from ₩45.00 loss in 3Q 2024). Revenue: ₩8.56b (up 32% from 3Q 2024). Net income: ₩838.4m (up ₩1.09b from 3Q 2024). Profit margin: 9.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue.New Risk • Apr 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩65.2b market cap, or US$46.0m).Reported Earnings • Mar 30Full year 2024 earnings released: ₩299 loss per share (vs ₩1,001 profit in FY 2023)Full year 2024 results: ₩299 loss per share (down from ₩1,001 profit in FY 2023). Revenue: ₩33.1b (up 16% from FY 2023). Net loss: ₩1.65b (down 134% from profit in FY 2023).분석 기사 • Feb 27A Piece Of The Puzzle Missing From J2KBIO Co., Ltd.'s (KOSDAQ:420570) 28% Share Price ClimbJ2KBIO Co., Ltd. ( KOSDAQ:420570 ) shareholders have had their patience rewarded with a 28% share price jump in the...분석 기사 • Feb 27J2KBIO Co., Ltd.'s (KOSDAQ:420570) Shares Leap 28% Yet They're Still Not Telling The Full StoryThe J2KBIO Co., Ltd. ( KOSDAQ:420570 ) share price has done very well over the last month, posting an excellent gain of...New Risk • Feb 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩66.1b market cap, or US$45.9m).공시 • Feb 15J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩55.0b market cap, or US$38.3m).Reported Earnings • Nov 12Third quarter 2024 earnings released: ₩45.00 loss per share (vs ₩283 profit in 3Q 2023)Third quarter 2024 results: ₩45.00 loss per share (down from ₩283 profit in 3Q 2023). Revenue: ₩6.51b (down 16% from 3Q 2023). Net loss: ₩250.3m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 36% growth forecast for the Biotechs industry in South Korea.Buy Or Sell Opportunity • Nov 08Now 24% overvaluedOver the last 90 days, the stock has fallen 28% to ₩13,270. The fair value is estimated to be ₩10,718, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 70% over the last year. Earnings per share has declined by 73%.Valuation Update With 7 Day Price Move • Oct 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩13,810, the stock trades at a trailing P/E ratio of 78.2x. Average forward P/E is 23x in the Biotechs industry in South Korea.분석 기사 • Aug 23J2KBIO (KOSDAQ:420570) Has A Rock Solid Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Buy Or Sell Opportunity • Aug 02Now 21% undervaluedOver the last 90 days, the stock has risen 5.9% to ₩18,900. The fair value is estimated to be ₩23,836, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 73% over the last year. Meanwhile, the company became loss making.New Risk • Jun 27New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.5b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risk Market cap is less than US$100m (₩135.5b market cap, or US$97.9m).Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩22,600, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 23x in the Biotechs industry in South Korea.Buy Or Sell Opportunity • May 10Now 23% overvaluedThe stock has been flat over the last 90 days, currently trading at ₩22,600. The fair value is estimated to be ₩18,317, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩16,340, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 21x in the Biotechs industry in South Korea.주주 수익률A420570KR BiotechsKR 시장7D-9.0%-7.9%-12.9%1Y-23.3%-2.6%117.6%전체 주주 수익률 보기수익률 대 산업: A420570은 지난 1년 동안 -2.6%의 수익을 기록한 KR Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: A420570은 지난 1년 동안 117.6%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A420570's price volatile compared to industry and market?A420570 volatilityA420570 Average Weekly Movement9.7%Biotechs Industry Average Movement11.1%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%안정적인 주가: A420570는 지난 3개월 동안 KR 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: A420570의 주간 변동성(10%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트201454Jaeseop Leewww.j2kbio.com바이오 벤처기업인 제이투케이바이오는 천연 소재와 미생물 발효를 통해 화장품, 기능성 식품, 생활용품의 유효 성분을 생산하는 기업입니다. 2014년에 설립되어 대한민국 청주에 본사를 두고 있습니다.더 보기J2KBIO Co., Ltd. 기초 지표 요약J2KBIO의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A420570 기초 통계시가총액₩45.26b순이익 (TTM)₩4.03b매출 (TTM)₩36.82b11.2x주가수익비율(P/E)1.2x주가매출비율(P/S)A420570는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A420570 손익계산서 (TTM)매출₩36.82b매출원가₩22.14b총이익₩14.68b기타 비용₩10.65b순이익₩4.03b최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)688.96총이익률39.86%순이익률10.94%부채/자본 비율1.2%A420570의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당3.2%현재 배당 수익률n/a배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/09 19:43종가2026/07/09 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스J2KBIO Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,510, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 14% over the past year.
Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 7.0% to ₩8,050. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 19%.
Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,790, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past year.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year.
Buy Or Sell Opportunity • Apr 09Now 20% overvaluedOver the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,510, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 14% over the past year.
Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 7.0% to ₩8,050. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 19%.
Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,790, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past year.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year.
Buy Or Sell Opportunity • Apr 09Now 20% overvaluedOver the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Mar 05Now 22% overvaluedOver the last 90 days, the stock has fallen 7.1% to ₩7,800. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.
공시 • Feb 13J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
분석 기사 • Dec 17J2KBIO Co., Ltd.'s (KOSDAQ:420570) Prospects Need A Boost To Lift SharesJ2KBIO Co., Ltd.'s ( KOSDAQ:420570 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,720, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 3.8% over the past year.
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ₩143 (vs ₩45.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩143 (up from ₩45.00 loss in 3Q 2024). Revenue: ₩8.56b (up 32% from 3Q 2024). Net income: ₩838.4m (up ₩1.09b from 3Q 2024). Profit margin: 9.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue.
New Risk • Apr 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩65.2b market cap, or US$46.0m).
Reported Earnings • Mar 30Full year 2024 earnings released: ₩299 loss per share (vs ₩1,001 profit in FY 2023)Full year 2024 results: ₩299 loss per share (down from ₩1,001 profit in FY 2023). Revenue: ₩33.1b (up 16% from FY 2023). Net loss: ₩1.65b (down 134% from profit in FY 2023).
분석 기사 • Feb 27A Piece Of The Puzzle Missing From J2KBIO Co., Ltd.'s (KOSDAQ:420570) 28% Share Price ClimbJ2KBIO Co., Ltd. ( KOSDAQ:420570 ) shareholders have had their patience rewarded with a 28% share price jump in the...
분석 기사 • Feb 27J2KBIO Co., Ltd.'s (KOSDAQ:420570) Shares Leap 28% Yet They're Still Not Telling The Full StoryThe J2KBIO Co., Ltd. ( KOSDAQ:420570 ) share price has done very well over the last month, posting an excellent gain of...
New Risk • Feb 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩66.1b market cap, or US$45.9m).
공시 • Feb 15J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩55.0b market cap, or US$38.3m).
Reported Earnings • Nov 12Third quarter 2024 earnings released: ₩45.00 loss per share (vs ₩283 profit in 3Q 2023)Third quarter 2024 results: ₩45.00 loss per share (down from ₩283 profit in 3Q 2023). Revenue: ₩6.51b (down 16% from 3Q 2023). Net loss: ₩250.3m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 36% growth forecast for the Biotechs industry in South Korea.
Buy Or Sell Opportunity • Nov 08Now 24% overvaluedOver the last 90 days, the stock has fallen 28% to ₩13,270. The fair value is estimated to be ₩10,718, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 70% over the last year. Earnings per share has declined by 73%.
Valuation Update With 7 Day Price Move • Oct 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩13,810, the stock trades at a trailing P/E ratio of 78.2x. Average forward P/E is 23x in the Biotechs industry in South Korea.
분석 기사 • Aug 23J2KBIO (KOSDAQ:420570) Has A Rock Solid Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Buy Or Sell Opportunity • Aug 02Now 21% undervaluedOver the last 90 days, the stock has risen 5.9% to ₩18,900. The fair value is estimated to be ₩23,836, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 73% over the last year. Meanwhile, the company became loss making.
New Risk • Jun 27New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.5b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risk Market cap is less than US$100m (₩135.5b market cap, or US$97.9m).
Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩22,600, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 23x in the Biotechs industry in South Korea.
Buy Or Sell Opportunity • May 10Now 23% overvaluedThe stock has been flat over the last 90 days, currently trading at ₩22,600. The fair value is estimated to be ₩18,317, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩16,340, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 21x in the Biotechs industry in South Korea.
